Alzamend Neuro IncNASDAQ:ALZNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6850
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6800/ 5
- Ask / Lots0.7300/ 5
- Open / Previous Close0.0000 / 0.6850
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALZN |
|---|---|---|
| 09:32 ET | 627 | 0.7 |
| 09:41 ET | 400 | 0.699899 |
| 10:01 ET | 199 | 0.68 |
| 10:08 ET | 105 | 0.68 |
| 10:14 ET | 4455 | 0.69 |
| 10:21 ET | 696 | 0.69 |
| 10:24 ET | 290 | 0.69 |
| 10:39 ET | 116 | 0.6999 |
| 11:02 ET | 5000 | 0.6937 |
| 11:18 ET | 269 | 0.7 |
| 11:51 ET | 700 | 0.670976 |
| 12:02 ET | 200 | 0.67 |
| 12:43 ET | 100 | 0.68 |
| 01:15 ET | 205 | 0.670101 |
| 01:21 ET | 100 | 0.675 |
| 01:24 ET | 200 | 0.675 |
| 01:28 ET | 650 | 0.679 |
| 01:44 ET | 10499 | 0.68 |
| 01:55 ET | 657 | 0.681 |
| 02:00 ET | 9282 | 0.678 |
| 03:12 ET | 975 | 0.7001 |
| 03:20 ET | 8335 | 0.7 |
| 03:23 ET | 1508 | 0.6925 |
| 03:57 ET | 106 | 0.685 |
| 03:59 ET | 678 | 0.685 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alzamend Neuro Inc | 4.7M | -0.3x | --- |
Synaptogenix Inc | 4.7M | -0.1x | --- |
Bio Path Holdings Inc | 4.6M | -0.1x | --- |
Burzynski Research Institute Inc | 4.6M | -3.9x | --- |
Kintara Therapeutics Inc | 4.5M | 0.0x | --- |
Neximmune Inc | 5.0M | -0.1x | --- |
Company Information
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.
Contact Information
- Headquarters
- 3480 Peachtree Road NE , Second Floor, Suite 103ATLANTA, GA, United States 30326
- Phone
- 302-636-5400
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- William Horne
- Chief Executive Officer, Director
- Stephan Jackman
- Vice Chairman of the Board
- Milton Ault
- Chief Financial Officer
- David Katzoff
- Executive Vice President, General Counsel, Director
- Henry Nisser
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $0.47 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
